Phaseline

Targets › FAK

FAK (Focal adhesion kinase 1): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout May 2027.

Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. (UniProt, Q05397)

Open in Phaseline: the race on FAK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ascentage Pharma GroupAPG-2449
Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor
FAK, ALK, ROS1Phase 1Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid CancerMay 2027
Amplia Therapeuticsnarmafotinib
focal adhesion kinase (FAK) inhibitor
FAKPhase 1Pancreatic Cancer MetastaticJul 2029

Conditions

Pancreatic Cancer Metastatic (1) Platinum-resistant Recurrent Ovarian Cancer (1) Advanced Solid Cancer (1)

Modalities

small molecule (2)

Companies

Amplia Therapeutics (1) Ascentage Pharma Group (1)

Related targets

ALK (1) ROS1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.